The Rare and Orphan Drug Commercialization Leader’s Guide to Patient Compliance

How a simple truth reimagines the management of orphan and rare disorders—for the benefit of all

You will learn:

  • The shortcomings of the legacy commercialization model
  • How a patients-first approach improves compliance and efficiency
  • 5 critical questions to ask your commercialization partners

“Optime Care is driving a patient compliance rate of nearly 90% for orphan and rare disease therapies. Compare that to industry standards of about 70% to 80% for specialty drugs and 50% for non-specialty or ‘regular’ drugs.”

Michelle Hefley, Chairman of the Board and Managing Partner, Optime Care
Optime Care White Paper

Get Your Free White Paper